Pages that link to "Q73586072"

The following pages link to Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells (Q73586072):

Displaying 42 items.

• Immunogenic targets for specific immunotherapy in multiple myeloma (Q26859007) (← links)
• Immunotherapy strategies for multiple myeloma: the present and the future (Q27021939) (← links)
• Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic (Q27023621) (← links)
• Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma (Q33732491) (← links)
• Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes (Q33785039) (← links)
• Novel immunotherapies (Q33822677) (← links)
• Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients (Q34075717) (← links)
• T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells (Q34191186) (← links)
• Recent advances in multiple myeloma immunotherapy (Q34668722) (← links)
• Dendritic cell vaccines in the treatment of multiple myeloma: advances and limitations (Q35039004) (← links)
• T cells in myeloma (Q35073256) (← links)
• Dendritic cell-based immunotherapy for the treatment of hematological malignancies (Q35127001) (← links)
• Dendritic cells and their potential therapeutic role in haematological malignancy (Q35614625) (← links)
• Clonal cytotoxic T cells in myeloma (Q35614630) (← links)
• Dendritic cell-based immunotherapy in multiple myeloma (Q35665926) (← links)
• Molecular monitoring of minimal residual disease in patients with multiple myeloma (Q35668677) (← links)
• Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine. (Q35699518) (← links)
• MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma (Q35842817) (← links)
• Immunotherapy using dendritic cells against multiple myeloma: how to improve? (Q35852574) (← links)
• Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study (Q35863376) (← links)
• Cellular immunotherapy using dendritic cells against multiple myeloma (Q35865581) (← links)
• Therapeutic idiotype vaccines for non-Hodgkin's lymphoma (Q35909323) (← links)
• Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma (Q35989451) (← links)
• Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth (Q36955402) (← links)
• Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma (Q37194598) (← links)
• Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia (Q37316845) (← links)
• Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma (Q37412334) (← links)
• Immunology and Immunotherapeutic Approaches in Multiple Myeloma (Q37867562) (← links)
• Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions (Q38014834) (← links)
• Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes (Q38532002) (← links)
• Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity (Q39265240) (← links)
• Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy (Q39882401) (← links)
• Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy (Q40223881) (← links)
• High-Level Expression of Cancer/Testis Antigen NY-ESO-1 and Human Granulocyte-Macrophage Colony-Stimulating Factor in Dendritic Cells with a Bicistronic Retroviral Vector (Q40632521) (← links)
• A Possible Role for Idiotype/Anti-idiotype B-T Cell Interactions in Maintaining Immune Memory. (Q41973429) (← links)
• The promise of the anti-idiotype concept. (Q42419120) (← links)
• Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. (Q45296414) (← links)
• Expansion of CD8 T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma (Q57904989) (← links)
• Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model (Q78691304) (← links)
• Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma (Q80119050) (← links)
• Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells (Q81510484) (← links)
• Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma (Q81872738) (← links)